Published in Virchows Arch on January 05, 2017
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature (2002) 7.07
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol (2015) 5.49
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res (2011) 5.30
Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature (2014) 4.88
Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol (2013) 4.72
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer (1996) 4.46
Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu Rev Immunol (2012) 4.27
Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst (2014) 4.20
PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J Clin Invest (2014) 3.54
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity (2013) 3.50
Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell (2014) 3.40
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med (2008) 3.35
The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov (2014) 3.32
Adoptive cell transfer as personalized immunotherapy for human cancer. Science (2015) 3.19
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell (2016) 2.65
The maternal microbiota drives early postnatal innate immune development. Science (2016) 2.49
The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med (2015) 2.48
Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res (2012) 2.48
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA (2016) 2.41
Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest (1996) 2.31
Immune cell promotion of metastasis. Nat Rev Immunol (2015) 2.15
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature (2015) 2.04
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science (2016) 1.95
Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol (2012) 1.90
The tumor microenvironment at a glance. J Cell Sci (2012) 1.79
Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res (2015) 1.77
Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science (2016) 1.76
Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res (2006) 1.68
A mechanism for expansion of regulatory T-cell repertoire and its role in self-tolerance. Nature (2015) 1.62
From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol (2013) 1.55
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A (2014) 1.52
The metastasis-promoting roles of tumor-associated immune cells. J Mol Med (Berl) (2013) 1.40
Macrophage polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages. PLoS One (2013) 1.40
CANCER IMMUNOLOGY. The "cancer immunogram". Science (2016) 1.27
Tertiary lymphoid structures in cancer and beyond. Trends Immunol (2014) 1.23
The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol (2014) 1.22
Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? Cancer Immunol Immunother (2011) 1.18
HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci (2007) 1.16
The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med (2016) 1.11
B cell-regulated immune responses in tumor models and cancer patients. Oncoimmunology (2013) 1.10
Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma. Cancer Immunol Immunother (2007) 1.08
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol (2015) 1.05
Landscape of tumor-infiltrating T cell repertoire of human cancers. Nat Genet (2016) 1.05
Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab. Clin Cancer Res (2015) 1.05
Prognostic impact of B-cell density in cutaneous melanoma. Cancer Immunol Immunother (2011) 1.05
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer (2015) 1.03
Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res (2005) 1.03
PD-L1hi B cells are critical regulators of humoral immunity. Nat Commun (2015) 1.02
SOX2 and nestin expression in human melanoma: an immunohistochemical and experimental study. Exp Dermatol (2011) 1.01
MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. Nat Commun (2015) 1.01
Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions. J Clin Pathol (2006) 0.99
Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma. Pigment Cell Melanoma Res (2015) 0.99
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun (2016) 0.97
Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity. Front Immunol (2015) 0.96
MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. Carcinogenesis (2012) 0.95
The immune microenvironment: a major player in human cancers. Int Arch Allergy Immunol (2014) 0.93
Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. J Natl Cancer Inst (2016) 0.91
NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures. Nat Commun (2015) 0.90
Prostaglandin E₂ constrains systemic inflammation through an innate lymphoid cell-IL-22 axis. Science (2016) 0.90
The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible "hard" lesions. Cancer Immunol Immunother (2010) 0.90
SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science (2016) 0.89
Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol (2014) 0.87
Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma. Int J Cancer (2013) 0.86
Phosphorylation status determines the opposing functions of Smad2/Smad3 as STAT3 cofactors in TH17 differentiation. Nat Commun (2015) 0.86
The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol (2016) 0.85
Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab. Cancer Res (2015) 0.85
Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome. Hum Pathol (2016) 0.85
Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. Expert Opin Biol Ther (2016) 0.84
IFNγ producing CD8(+) T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas. Oncoimmunology (2015) 0.84
CD103+ dendritic cells producing interleukin-12 in anticancer immunosurveillance. Cancer Cell (2014) 0.84
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol (2016) 0.83
Transforming growth factor-β and Notch ligands act as opposing environmental cues in regulating the plasticity of type 3 innate lymphoid cells. Sci Signal (2016) 0.83
Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy. Mol Immunol (2013) 0.82
Immunomics in Skin Cancer - Improvement in Diagnosis, Prognosis and Therapy Monitoring. Curr Proteomics (2013) 0.82
Plasma cells within the infiltrate of primary cutaneous malignant melanoma of the skin. A confirmation of its histoprognostic value. Am J Dermatopathol (1987) 0.82
Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma. J Transl Med (2015) 0.81
Influence of human immune cells on cancer: studies at the University of Colorado. Immunol Res (2013) 0.80
Prediction of lymph node metastases from the histologic features of primary cutaneous malignant melanomas. Am J Dermatopathol (1984) 0.80
Memory programming in CD8(+) T-cell differentiation is intrinsic and is not determined by CD4 help. Nat Commun (2015) 0.80
Gauging the Long-Term Benefits of Ipilimumab in Melanoma. J Clin Oncol (2015) 0.80
Ndrg1 is a T-cell clonal anergy factor negatively regulated by CD28 costimulation and interleukin-2. Nat Commun (2015) 0.79
A New Biological Feature of Natural Killer Cells: The Recognition of Solid Tumor-Derived Cancer Stem Cells. Front Immunol (2016) 0.79
Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanoma. Nat Rev Clin Oncol (2015) 0.79
Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology (2016) 0.79
Melanoma Cells Can Adopt the Phenotype of Stromal Fibroblasts and Macrophages by Spontaneous Cell Fusion in Vitro. Int J Mol Sci (2016) 0.79
Antigen receptor-mediated depletion of FOXP3 in induced regulatory T-lymphocytes via PTPN2 and FOXO1. Nat Commun (2015) 0.78
Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy. Front Immunol (2016) 0.78
Resistance of novel mouse strains different in MHC class I and the NKC domain to the development of experimental tumors. Int J Oncol (2016) 0.78
Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma. Oncoimmunology (2015) 0.77